Top 50 Medical VC (Venture Capital) Funds in Australia in January 2026

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.

Right Click Capital - Australian Venture Capital Firm

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.

Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

FundWA is a Western Australian venture capital fund that invests in technology-enabled innovative businesses in Western Australia.

Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Larsen Ventures is a lean, driven and strategic venture investment firmWe believe in alignment, long-term thinking & investor due diligence
 We like metrics, traction & perseverance
 We invest in people
1/3 of our focus is on Health and Education; 
We like the thematic & overall gains for society2/3 of our time is spentlearning from peers, digging into research, 
chasing leads & hanging out on caffeinated zooms in the endless search for;Founders with Traction 
Founders with Insight
 Founders with Perseverance and Courage 
Founders with an innate ability to question EverythingWe have patient capital that engages & contributes to your Journey 
Accelerate your business with our portfolios' intellectual capital

Tyson & Blake We identify growth companies with unique approaches and innovative technologies that have the potential to make a profound contribution to society.We develop inspiring businesses that share our goals and our values.We create a positive impact and long-term value for our investors, the companies we invest in and the communitieswe live in.

Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.

Resource Capital Funds is a mining-focused alternative investments firm that partners with companies to build strong, successful, and sustainable businesses.

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

SG Hiscock

As Australia's national science agency and innovation catalyst, we solve the greatest challenges through innovative science and technology.

A multi-stage investment fund focused on Consumer, Enterprise, Fintech, Frontier, Healthcare, & PropTech

Pollenizer is a co-founder of start-up web businesses in Australia. They partner with strong founders and take equity stakes at a concept stage on consumer and SaaS businesses. The skill sets cover technology, marketing and capital raising. They also occasionally make seed investments. Their businesses include;* * ** * * * * * * * * * Their team includes;* Phil Morle, ex-CTO of Kazaa, Omnidrive.* Mick Liubinskas, ex-CMO of Kazaa, Tangler, ZaprThey are also investors and partners with

OIF is a venture capital firm focusing on partnering with entrepreneurs building businesses.

Archangel is an early stage venture capital fund based in Australia. We work with great founders and investors to build game changing companies together.

Privately Held Companies

A venture capital fund for ambitious Australian & New Zealand B2B technology ventures seeking to expand to the UK or USA. Tribe Global Ventures.

Victorian Government is an online platform that provides state government information and services to Victorians. Its users have the ability access the platform on the web or on their mobile devices.

Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.

CVC has seven complementary strategies across private equity, secondaries and credit, through which we invest on behalf of pension funds and other leading institutions

Great tech startup businesses are built by amazing product teams

Get Award Winning cover. Voted Outstanding Value Health Insurance for 16 Consecutive Years. Choose from flexible cover options & join online today.

Scalare Partners is more than a technology investment fund. We provide critical funding and resourcing

TEN13 is Australia's leading Venture Capital Syndicate.

Salus Ventures is a venture capital firm.

Prtnr is an investment firm.

Black Sheep Capital is making its mark as a preferred investment capital provider due to their 'Everyone Wins' approach. Their philosophy is to work with their investment partners to create and grow opportunities where they can all enjoy success. Through this approach, they have been able to create a diverse portfolio of investments thatcontinues to grow.

Titanium Ventures is the results-oriented VC partner to the most promising technology startups. Accelerating extraordinary companies and fueling growth of standout disruptors.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.

AirTree is a venture capital firm investing in Australian and New Zealand technology founders from seed stage or earlier.

Side Stage Ventures is a founder-led seed fund backing outlier founders in Australia. We write the first cheque into the best early stage companies. Then we lean in to help the founders build & scale.

With origins in owning and operating Australian pharmacies, Soul Patts has evolved into a diversified investment house investing across a range of industries and asset classes, including listed equities, private equity, credit, and property.